SAREPTA THERAPEUTICS INC (SRPT)

Sarepta Therapeutics (SRPT) Q3 2024 Earnings Call Transcript

SRPT earnings call for the period ending September 30, 2024.

Sarepta Therapeutics Announces Third Quarter 2024 Financial Results and Recent Corporate Developments

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Interesting SRPT Put And Call Options For December 13th

Sarepta Therapeutics to Announce Third Quarter 2024 Financial Results

Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up

The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma.

2 High-Flying Growth Stocks With Massive Upside Potential

These innovative drugmakers have potential catalysts ahead.

RSI Alert: Sarepta Therapeutics (SRPT) Now Oversold

Better Biotech Stock: Wave Life Sciences vs. Sarepta Therapeutics

These two could become direct competitors relatively soon.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2024 World Muscle Society Congress

Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors

These 2 Biotech Stocks Are Set to Soar

Innovative drugmakers developing treatments for conditions with high unmet needs can produce lucrative wins.

SRPT Makes Notable Cross Below Critical Moving Average

Relative Strength Alert For Sarepta Therapeutics

Sarepta Therapeutics Announces Recipients of the 7th Annual Route 79, The Duchenne Scholarship Program, for the 2024-2025 Academic Year

Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Its C-Suite Just Fled The Building

The company is hoping to rival Sarepa's Exondys 51. But three executives just departed on what is calls "unprecedented" test results.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Sarepta Therapeutics Moves Up In Market Cap Rank, Passing Carmax

Tuesday 8/20 Insider Buying Report: SRPT, ALGN

2 Biotech Stocks to Buy Hand Over Fist in August

Both of these biotechs are highly innovative companies.

How Avidity Biosciences Just Dropped The Hammer On Sarepta Therapeutics

The company is coming up fast with a platform that could take on several of Sarepta's approved treatments.